Quarterly Earnings

RLJ Lodging Trust's stellar Q2 results weren't just a market beat; they were a validation of a shrewd strategy combining a lifestyle pivot with bold finance.

While others wait for the housing market to recover, James Hardie is building its own boom. A deep dive into the strategic execution driving its success.

WM Technology's Q2 results show a puzzling split: higher net income but falling revenue and key metrics. Is this savvy cost-cutting or a sign of deeper trouble?

Morgan Stanley's lending arm maintains its dividend, but rising non-accruals and a NAV dip reveal the defensive maneuvers required in a cooling credit market.

A steep revenue drop and slashed guidance at Xponential Fitness raise urgent questions about its franchise model and whether the boutique fitness craze has hit a wall.

AIG's strong Q2 results beat profit estimates, powered by underwriting discipline as it completes its strategic pivot away from Corebridge Financial.

X4 Pharmaceuticals secures a key European approval and overhauls its pivotal trial, signaling a major strategic shift backed by a newly extended cash runway.

With record revenues and a raised outlook, Ryman Hospitality's Q2 results reveal more than just strong bookings—they map the future of group travel.

Clarus Corp. stunned with a Q2 profit, but a $6.1M tariff refund clouds the picture. As one segment soars and another sinks, a strategic review looms.

Beyond strong Q2 earnings, a forensic look at CBL's strategy reveals how aggressive debt restructuring and portfolio reinvention are creating a new model for retail.

The food-tech giant declared a routine dividend, but behind the curtain of record orders lies a significant asset writedown, raising questions about its health.

Bimini Capital's strong Q2 results reveal a radical shift, trading its mortgage portfolio for asset manager TJIM, creating a new, more stable model.

ESCO Technologies reports a stellar Q3 with 38% adjusted EPS growth and a record $1.5B backlog, proving its acquisition strategy is a powerful engine for growth.

A 5% revenue dip masks a surge in users and a high-stakes bet on a new 'Predictions' product. Is DraftKings sacrificing a quarter to win the war?

Starling Oncology just hit positive Adjusted EBITDA, a milestone for its value-based care model. Is this the inflection point for profitability in oncology?

Karat Packaging's profits surged 168% thanks to a massive one-time tariff refund. A deep dive reveals the real story lies in its strategic growth.

Despite a dip in legacy revenue, Autoscope Technologies posts higher profits and doubles down on AI solutions aimed at making cities smarter and safer for all.

With its Duchenne therapy nearing a pivotal FDA meeting, Solid Biosciences isn't just developing a drug; it's building a network for genetic repair.

After 15 years and 41 straight profitable quarters, PubMatic's CFO Steve Pantelick is retiring. A deep dive into his legacy and the ad tech firm's future.

Q2 results show growth, but rising costs and heavy spending underscore the pressure on Granite Ridge to hit its 2027 free cash flow inflection point.